Lifileucel：首个获准用于实体瘤的细胞疗法。

IF 14.3 1区医学 Q1 ONCOLOGY Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-05-09 DOI:10.1016/j.trecan.2024.04.003

Max Julve, Mark P Lythgoe, James Larkin, Andrew J S Furness

{"title":"Lifileucel：首个获准用于实体瘤的细胞疗法。","authors":"Max Julve, Mark P Lythgoe, James Larkin, Andrew J S Furness","doi":"10.1016/j.trecan.2024.04.003","DOIUrl":null,"url":null,"abstract":"The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"475-477"},"PeriodicalIF":14.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lifileucel: the first cellular therapy approved for solid tumours.\",\"authors\":\"Max Julve, Mark P Lythgoe, James Larkin, Andrew J S Furness\",\"doi\":\"10.1016/j.trecan.2024.04.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"475-477\"},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2024.04.003\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.04.003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

美国食品和药物管理局（FDA）批准使用lifileucel治疗晚期黑色素瘤，这是首个用于实体瘤临床治疗的细胞疗法。在此，我们总结了这一具有里程碑意义的批准，考虑了相关的监管途径，并评估了为确保有效实施这种先进的 "活 "疗法所面临的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Lifileucel: the first cellular therapy approved for solid tumours.

The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.

期刊最新文献

Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors? Metabolic landscape of disseminated cancer dormancy. Mechanisms governing lineage plasticity and metabolic reprogramming in cancer. Trends in cancer imaging. Epigenetic control of immunoevasion in cancer stem cells.